News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|June 12, 2024

Unveiling Treatment Gaps: Expert Perspectives on the Undermanagement of Patients with Atopic Dermatitis and Childbearing Potential

Author(s)Elizabeth Kiracofe, MD, FAAD, Jenny Murase, MD, FAAD

Dr. Elizabeth Kiracofe, MD, FAAD, and Dr. Jenny Murase, MD, introduce a discussion on the undertreatment of patients with atopic dermatitis, particularly focusing on pregnant individuals and those of childbearing age.

Episodes in this series

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 1 Unveiling Treatment Gaps: Expert Perspectives on the Undermanagement of Patients with Atopic Dermatitis and Childbearing Potential

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 2 Fostering Communication: Promoting Dialogue on Atopic Dermatitis Treatment Concerns in Patients of Childbearing Potential

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 3 Exploring Changes in Atopic Dermatitis Severity Across the Pregnancy Journey

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 4 Navigating Treatment Choices: Balancing Treatment Options for Childbearing-Age Patients

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 5 Insights on Transcription Binding in Atopic Dermatitis

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 6 Informed Decisions: Dialogue with Treatment-Naïve Pregnant Patients Regarding Systemic Atopic Dermatitis Treatment Options

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 7 Managing Atopic Dermatitis Treatment Escalation in Pregnancy: Considerations and Approaches

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 8 Urgent Need for Consensus on Systemic Treatments for Atopic Dermatitis in Childbearing-Age Populations

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 9 Considerations for Breastfeeding, Lactation, and Postpartum in Family Planning Patients with Atopic Dermatitis

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 10 Concluding Remarks: Systemic Treatment Considerations for Atopic Dermatitis in Patients of Childbearing Potential

EP. 11 Ten Clinical Considerations to Manage AD in Pregnant Patients

EP. 11 Ten Clinical Considerations to Manage AD in Pregnant Patients

Video content above is prompted by the following question(s):

Please comment on the issue of undertreatment and underdosing in pregnant populations, even when data supports their potential efficacy and safety.
How might this bias hinder optimizing care and the willingness to use potentially higher-risk but more efficacious systemic therapies?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Joseph Gorelick, MSN, FNP-C

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

Dermatology Conferences and Meetings Calendar: December 2025

Rethinking Pathogenesis and Severity Assessment in Chronic Hand Eczema

© 2025 MJH Life Sciences^®

All rights reserved.